2023 American College of Rheumatology (ACR)/American College of Chest Physicians (CHEST) Guideline for the Treatment of Interstitial Lung Disease in People with Systemic Autoimmune Rheumatic Diseases
Sindhu R Johnson,Elana J Bernstein,Marcy B Bolster,Jonathan H Chung,Sonye K Danoff,Michael D George,Dinesh Khanna,Gordon Guyatt,Reza D Mirza,Rohit Aggarwal,Aberdeen Allen Jr,Shervin Assassi,Lenore Buckley,Hassan A Chami,Douglas S Corwin,Paul F Dellaripa,Robyn T Domsic,Tracy J Doyle,Catherine Marie Falardeau,Tracy M Frech,Fiona K Gibbons,Monique Hinchcliff,Cheilonda Johnson,Jeffrey P Kanne,John S Kim,Sian Yik Lim,Scott Matson,Zsuzsanna H McMahan,Samantha J Merck,Kiana Nesbitt,Mary Beth Scholand,Lee Shapiro,Christine D Sharkey,Ross Summer,John Varga,Anil Warrier,Sandeep K Agarwal,Danielle Antin-Ozerkis,Bradford Bemiss,Vaidehi Chowdhary,Jane E Dematte D'Amico,Robert Hallowell,Alicia M Hinze,Patil A Injean,Nikhil Jiwrajka,Elena K Joerns,Joyce S Lee,Ashima Makol,Gregory C McDermott,Jake G Natalini,Justin M Oldham,Didem Saygin,Kimberly Showalter Lakin,Namrata Singh,Joshua J Solomon,Jeffrey A Sparks,Marat Turgunbaev,Samera Vaseer,Amy Turner,Stacey Uhl,Ilya Ivlev
DOI: https://doi.org/10.1002/art.42861
Abstract:Objective: We provide evidence-based recommendations regarding the treatment of interstitial lung disease (ILD) in adults with systemic autoimmune rheumatic diseases (SARDs). Methods: We developed clinically relevant population, intervention, comparator, and outcomes questions. A systematic literature review was then performed, and the available evidence was rated using the Grading of Recommendations, Assessment, Development, and Evaluation methodology. A panel of clinicians and patients reached consensus on the direction and strength of the recommendations. Results: Thirty-five recommendations were generated (including two strong recommendations) for first-line SARD-ILD treatment, treatment of SARD-ILD progression despite first-line ILD therapy, and treatment of rapidly progressive ILD. The strong recommendations were against using glucocorticoids in systemic sclerosis-ILD as a first-line ILD therapy and after ILD progression. Otherwise, glucocorticoids are conditionally recommended for first-line ILD treatment in all other SARDs. Conclusion: This clinical practice guideline presents the first recommendations endorsed by the American College of Rheumatology and American College of Chest Physicians for the treatment of ILD in people with SARDs.